GlassScriptPhysician profile
Monte R Middleton
NPI 1669796892
$2,912.11
in general payments reported to CMS, 2019-2025
15 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $182 · 2022: $237 · 2023: $660 · 2024: $710 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413 · Education: $79.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.28 |
| Education | $79.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $485.42 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $373.55 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $314.95 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $314.88 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $303.43 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $262.20 | 2021-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $220.25 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $148.84 | 2022-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $117.35 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $97.77 | 2023-2025 | Qelbree, Qelbree |
| Indivior INC. | $76.71 | 2022-2024 | Perseris |
| Corium, LLC | $53.94 | 2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $52.50 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $46.74 | 2023-2024 | Trintellix |
| Axsome Therapeutics, INC. | $43.58 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monte Middleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.